As per reports, the European planemaker Airbus has withdrawn from a U.S. government-named panel reviewing Boeing’s (BA) safety processes and how they influence Boeing’s safety culture after two fatal 737 MAX crashes killing 346 people. The Federal Aviation Administration (FAA) panel included James Tidball, head of the certification for Airbus Americas among others. Airbus expressed that it appreciated the FAA’s recognition of Tidball’s impartiality around safety but given Tidball decided to recuse himself from this working panel.
Congress has directed the agency to appoint a panel by early 2021, to review how the FAA certifies new airplanes, but the FAA missed that deadline.
Dow 30 component Boeing (NYSE: BA) is the world’s largest aerospace company and leading manufacturer of commercial jetliners and defense, space, and security systems. To learn more about Boeing (BA) and to track its ongoing progress please visit the Vista Partners Boeing (BA) Coverage Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
Consider visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.
READ THIS PROGRESS REPORT TOO…
On January 10, InMed Pharmaceuticals Inc. (Nasdaq: INM) issued a press release, which outlined their key accomplishments from 2022 and provided business update and catalysts for 2023 including the following interesting milestones for 2023:
- Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
- Progress preclinical research in glaucoma in preparation for human trials
- Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
“Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how. Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters,” stated Eric A. Adams, InMed President and CEO.REVIEWING InMed’s 2022 ACCOMPLISHMENTS
INM-755 in Epidermolysis Bullosa
-
Activated 11 clinical trial sites in seven countries for the Phase 2 study
-
Expanded from adult subjects to include adolescents following independent review of early safety data
-
Progressed clinical trial with enrollment and treatment of 15 patients, with the 16th patient enrolled for treatment in early January 2023
To review the balance of the this report please follow us by clicking here!
